Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management

Abstract Multiple myeloma (MM), a hematologic malignancy characterized by the clonal expansion of plasma cells within the bone marrow, is associated with severe health complications, including osteolytic bone lesions that significantly increase the risk of fractures, leading to higher morbidity and...

Full description

Saved in:
Bibliographic Details
Main Authors: Tiziana Bruno, Valeria Catena, Giovanni Blandino, Maurizio Fanciulli, Silvia Di Agostino
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-024-03248-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846111968156450816
author Tiziana Bruno
Valeria Catena
Giovanni Blandino
Maurizio Fanciulli
Silvia Di Agostino
author_facet Tiziana Bruno
Valeria Catena
Giovanni Blandino
Maurizio Fanciulli
Silvia Di Agostino
author_sort Tiziana Bruno
collection DOAJ
description Abstract Multiple myeloma (MM), a hematologic malignancy characterized by the clonal expansion of plasma cells within the bone marrow, is associated with severe health complications, including osteolytic bone lesions that significantly increase the risk of fractures, leading to higher morbidity and mortality rates. One intriguing protein in this context is the RNA polymerase binding factor Che-1/AATF (Che-1), which has emerged as a potential player in the survival and proliferation of myeloma cells. Hippo pathway has been shown to be an important mediator of oncogenesis in solid tumors, especially for its role in shaping a tumor microenvironment favorable to cancer maintenance and spread. The Hippo pathway is also implicated in the pathogenesis of the osteolytic lesions that occurs in MM, since it deregulates the activities of mesenchymal populations of the bone matrix. In this commentary we wish to highlight some new molecular aspects elucidated in the paper by Bruno et al. regarding the proliferation of MM and the onset of bone lesions [Leukemia 38:877–882, 1]. A series of recent findings has revealed a crosstalk between the RNA polymerase binding factor Che-1 and the HIPPO downstream co-transcriptional factor TAZ, bringing to light new emerging molecular targets in MM to limit the development of bone lesions.
format Article
id doaj-art-433eaca3e09a4fe0afbd37bd50e15e57
institution Kabale University
issn 1756-9966
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Journal of Experimental & Clinical Cancer Research
spelling doaj-art-433eaca3e09a4fe0afbd37bd50e15e572024-12-22T12:55:32ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662024-12-014311410.1186/s13046-024-03248-9Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease managementTiziana Bruno0Valeria Catena1Giovanni Blandino2Maurizio Fanciulli3Silvia Di Agostino4SAFU Laboratory, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer InstituteSAFU Laboratory, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer InstituteTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer InstituteSAFU Laboratory, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer InstituteDepartment of Health Sciences, Magna Graecia University of CatanzaroAbstract Multiple myeloma (MM), a hematologic malignancy characterized by the clonal expansion of plasma cells within the bone marrow, is associated with severe health complications, including osteolytic bone lesions that significantly increase the risk of fractures, leading to higher morbidity and mortality rates. One intriguing protein in this context is the RNA polymerase binding factor Che-1/AATF (Che-1), which has emerged as a potential player in the survival and proliferation of myeloma cells. Hippo pathway has been shown to be an important mediator of oncogenesis in solid tumors, especially for its role in shaping a tumor microenvironment favorable to cancer maintenance and spread. The Hippo pathway is also implicated in the pathogenesis of the osteolytic lesions that occurs in MM, since it deregulates the activities of mesenchymal populations of the bone matrix. In this commentary we wish to highlight some new molecular aspects elucidated in the paper by Bruno et al. regarding the proliferation of MM and the onset of bone lesions [Leukemia 38:877–882, 1]. A series of recent findings has revealed a crosstalk between the RNA polymerase binding factor Che-1 and the HIPPO downstream co-transcriptional factor TAZ, bringing to light new emerging molecular targets in MM to limit the development of bone lesions.https://doi.org/10.1186/s13046-024-03248-9Multiple myelomaChe-1TAZmicroRNAMicroenvironmentBone
spellingShingle Tiziana Bruno
Valeria Catena
Giovanni Blandino
Maurizio Fanciulli
Silvia Di Agostino
Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
Journal of Experimental & Clinical Cancer Research
Multiple myeloma
Che-1
TAZ
microRNA
Microenvironment
Bone
title Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
title_full Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
title_fullStr Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
title_full_unstemmed Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
title_short Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
title_sort molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management
topic Multiple myeloma
Che-1
TAZ
microRNA
Microenvironment
Bone
url https://doi.org/10.1186/s13046-024-03248-9
work_keys_str_mv AT tizianabruno molecularinsightsunlockingtherapeuticpotentialformultiplemyelomaandbonediseasemanagement
AT valeriacatena molecularinsightsunlockingtherapeuticpotentialformultiplemyelomaandbonediseasemanagement
AT giovanniblandino molecularinsightsunlockingtherapeuticpotentialformultiplemyelomaandbonediseasemanagement
AT mauriziofanciulli molecularinsightsunlockingtherapeuticpotentialformultiplemyelomaandbonediseasemanagement
AT silviadiagostino molecularinsightsunlockingtherapeuticpotentialformultiplemyelomaandbonediseasemanagement